Cronos GroupCRON +3.31%86 FCF Margin % is 19.75% as of Mar. 2026. GuruFocus rates CRON with a GF Score™ of 86/100 and a GF Value™ of $3.45 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 958 Drug Manufacturers companies, Cronos Group ranks better than 83.51% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cronos Group's Free Cash Flow for the
three
months ended in Mar. 2026 was $8.9 Mil. Cronos Group's Revenue for the
three
months ended in Mar. 2026 was $45.2 Mil. Therefore, Cronos Group's FCF Margin % for the quarter that ended in Mar. 2026 was 19.75%.
The historical rank and industry rank for Cronos Group's FCF Margin % or its related term are showing as below:
CRON'
s FCF Margin % Range Over the Past 10 Years
Min: -1443.27 Med: -321.39 Max: 16.42
Current: 16.42
During the past 12 years, the highest FCF Margin % of Cronos Group was 16.42%. The lowest was -1443.27%. And the median was -321.39%.
CRON's FCF Margin % is ranked better than 83.51% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs CRON: 16.42
Cronos Group FCF Margin % Related Terms
Cronos Group FCF Margin % Historical Data
* Premium members only.
The historical data trend for Cronos Group's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cronos Group's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (CRON) has a FCF Margin % of 19.75% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #158 out of 958 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is Cronos Group's FCF Margin % too high?
Cronos Group's current FCF Margin % is 19.75%. The Drug Manufacturers industry median FCF Margin % is 2.45. Cronos Group's value of 19.75% is 707.8% above this industry median. Based on the distribution chart, Cronos Group ranks #158 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cronos Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #158 out of 958 companies for FCF Margin %. This places Cronos Group in the top 17% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. Cronos Group's value of 19.75% is 707.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current FCF Margin % of 19.75% is 707.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current FCF Margin % is 19.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (CRON) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.45, compared to a current price of $2.81 — trading 18.6% below its estimated fair value. The current FCF Margin % is 19.75% and 707.8% above the Drug Manufacturers industry median of 2.45. Cronos Group's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cronos Group (CRON), the current FCF Margin % is 19.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (CRON) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of $2.81 is trading 18.6% below its estimated GF Value™ of $3.45.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for CRON:
FCF Margin %: 19.75%
GF Value™: $3.45 vs. price of $2.81 (18.6% below fair value)
Industry Position: 707.8% above the Drug Manufacturers median (#158 of 958)
No single metric tells the full story. See the CRON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
86GF Score
Get the complete analysis for CRON
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRON has been successfully added to your 
